Your browser doesn't support javascript.
Self-assembling synthetic nanoadjuvant scaffolds cross-link B cell receptors and represent new platform technology for therapeutic antibody production.
Senapati, Sujata; Darling, Ross J; Ross, Kathleen A; Wannemeuhler, Michael J; Narasimhan, Balaji; Mallapragada, Surya K.
  • Senapati S; Department of Chemical and Biological Engineering, Iowa State University, Ames, IA, USA.
  • Darling RJ; Department of Veterinary Microbiology and Preventive Medicine, Iowa State University, Ames, IA, USA.
  • Ross KA; Department of Chemical and Biological Engineering, Iowa State University, Ames, IA, USA.
  • Wannemeuhler MJ; Nanovaccine Institute, Iowa State University, Ames, IA, USA.
  • Narasimhan B; Department of Veterinary Microbiology and Preventive Medicine, Iowa State University, Ames, IA, USA.
  • Mallapragada SK; Nanovaccine Institute, Iowa State University, Ames, IA, USA.
Sci Adv ; 7(32)2021 08.
Article in English | MEDLINE | ID: covidwho-1343936
ABSTRACT
Host antibody responses are pivotal for providing protection against infectious agents. We have pioneered a new class of self-assembling micelles based on pentablock copolymers that enhance antibody responses while providing a low inflammatory environment compared to traditional adjuvants. This type of "just-right" immune response is critical in the rational design of vaccines for older adults. Here, we report on the mechanism of enhancement of antibody responses by pentablock copolymer micelles, which act as scaffolds for antigen presentation to B cells and cross-link B cell receptors, unlike other micelle-forming synthetic block copolymers. We exploited this unique mechanism and developed these scaffolds as a platform technology to produce antibodies in vitro. We show that this novel approach can be used to generate laboratory-scale quantities of therapeutic antibodies against multiple antigens, including those associated with SARS-CoV-2 and Yersinia pestis, further expanding the value of these nanomaterials to rapidly develop countermeasures against infectious diseases.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Yersinia pestis / Recombinant Fusion Proteins / Receptors, Antigen, B-Cell / Antigen Presentation / Cross-Linking Reagents / Spike Glycoprotein, Coronavirus / Antibody Formation Type of study: Randomized controlled trials Topics: Vaccines Limits: Animals Language: English Year: 2021 Document Type: Article Affiliation country: Sciadv.abj1691

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Yersinia pestis / Recombinant Fusion Proteins / Receptors, Antigen, B-Cell / Antigen Presentation / Cross-Linking Reagents / Spike Glycoprotein, Coronavirus / Antibody Formation Type of study: Randomized controlled trials Topics: Vaccines Limits: Animals Language: English Year: 2021 Document Type: Article Affiliation country: Sciadv.abj1691